Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited is a global generic and specialty pharmaceutical manufacturer headquartered in Israel, with significant operations in the United States and Europe. The company is researched by investors seeking exposure to the generic drug market and specialty therapeutics in areas like CNS, respiratory, and oncology.
Get a full AI research report on TEVA
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Teva Pharmaceutical Industries Limited do?
Teva generates revenue by developing, manufacturing, and distributing generic medicines across multiple dosage forms (tablets, injectables, inhalants, patches) and specialty branded products including COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and AUSTEDO (tardive dyskinesia). The company also operates an active pharmaceutical ingredients (API) business, contract manufacturing services, and an out-licensing platform. With a gross margin of 52.5%, Teva relies on volume and scale in the competitive generic market while leveraging branded specialty products for higher-margin revenue.
Bull case
- ✓Gross margin of 52.5% demonstrates pricing power and operational efficiency in a competitive generic drug market.
- ✓Specialty branded portfolio (COPAXONE, AJOVY, AUSTEDO) provides higher-margin revenue streams less exposed to generic price compression.
- ✓Forward P/E of 42.6 is substantially lower than trailing P/E of 64.8, suggesting market expectations for earnings growth or multiple compression.
- ✓PEG ratio of 0.68 indicates valuation may be reasonable relative to expected earnings growth trajectory.
- ✓Global geographic diversification across the US, Europe, Israel, and international markets reduces dependence on any single regulatory or market environment.
Bear case
- ✗Debt-to-equity ratio of 217.8% signals very high financial leverage and substantial debt burden relative to shareholder equity.
- ✗Current ratio of 0.879 and quick ratio of 0.457 indicate potential near-term liquidity constraints and limited ability to cover short-term obligations.
- ✗Operating margin of only 4.0% and net margin of 4.1% show thin profitability despite the 52.5% gross margin, reflecting high operating and financing costs.
- ✗Generic drug market faces persistent pricing pressure and commoditization, limiting pricing power and requiring continuous cost management.
- ✗Return on equity of 9.7% and return on assets of 5.1% are modest, raising questions about capital efficiency and shareholder value creation relative to debt levels.
TEVA valuation & financial health
Teva trades at a trailing P/E of 64.8 and forward P/E of 42.6, with a PEG ratio of 0.68 suggesting moderate valuation relative to growth expectations. However, the company's financial health shows material stress: a debt-to-equity ratio of 217.8% indicates heavy leverage, while current and quick ratios below 0.9 and 0.5 respectively signal liquidity tightness. The 52.5% gross margin is healthy, but operating and net margins of 4.0% and 4.1% reveal that most gross profit is consumed by operating expenses and debt servicing. ROE of 9.7% and ROA of 5.1% are modest, and the company pays no dividend, suggesting capital is directed toward debt reduction or reinvestment rather than shareholder distributions.
The bottom line
Teva presents a tension between a fundamentally sound specialty and generic pharmaceutical business with global scale and reasonable forward valuation, and a heavily leveraged balance sheet with tight liquidity that constrains financial flexibility. Key factors to weigh include the company's ability to grow earnings to justify the forward P/E multiple, progress on debt reduction, and the sustainability of specialty product margins amid generic competition. Investors researching Teva should monitor quarterly earnings trends, debt refinancing activity, and competitive pressures in its core therapeutic areas to assess whether current valuation reflects realistic recovery or embedded execution risk.
Frequently asked questions
What does Teva Pharmaceutical Industries Limited do?
Teva develops, manufactures, and distributes generic medicines in multiple dosage forms, specialty branded pharmaceuticals (including treatments for multiple sclerosis, migraine, and tardive dyskinesia), active pharmaceutical ingredients, and contract manufacturing services. The company operates globally with major presence in the US, Europe, and Israel.
Is TEVA a good stock to research?
Teva is relevant for investors researching the generic and specialty pharmaceutical sector. The company has a large global footprint and specialty product portfolio, but also carries high debt levels and operates in a competitive generic market with pricing pressure. Research should focus on debt trajectory, earnings growth, and competitive positioning.
What is Teva's valuation?
Teva trades at a trailing P/E of 64.8 and forward P/E of 42.6, with a PEG ratio of 0.68. The forward multiple is substantially lower than the trailing multiple, reflecting market expectations for earnings improvement or multiple compression. The EV/EBITDA of 35.3 is elevated relative to many peers.
Is TEVA overvalued or undervalued?
Valuation assessment depends on earnings growth assumptions and debt reduction expectations. The forward P/E of 42.6 and PEG of 0.68 suggest the market is pricing in meaningful earnings growth, while the high trailing P/E reflects recent profitability challenges. Investors should evaluate whether management's guidance supports forward earnings expectations.
What are the main risks for TEVA investors?
Key risks include high debt-to-equity leverage (217.8%), tight liquidity (current ratio 0.879), thin operating margins (4.0%), and ongoing generic drug pricing pressure. Additionally, specialty product market share and patent cliffs on branded drugs could impact future revenue and margins.
Does Teva pay a dividend?
No, Teva does not currently pay a dividend. The company's dividend yield is 0% and payout ratio is 0%, indicating that capital is retained for debt reduction, operational needs, or reinvestment rather than distributed to shareholders.
Research TEVA with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.